Navigation Links
Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
Date:10/24/2011

PINE BROOK, N.J., Oct. 24, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the development of antibody therapeutics, announced today that it is initiating a new clinical study to further demonstrate the safety of Anthim (ETI-204), the company's anti-toxin in late-stage development for prevention of disease and death from exposure to inhaled anthrax. The company also announced it has successfully manufactured Anthim at commercial scale. Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people following a biowarfare attack.

(Logo: http://photos.prnewswire.com/prnh/20090420/NY01624LOGO)

The double blind, placebo-controlled dose-escalating study will include a total of 108 healthy human subjects and is designed to collect additional safety and pharmacokinetic (PK) data on Anthim.

"Our development timeline for Anthim is right on track, and this additional safety and PK data will further prove Anthim's utility as a strong candidate for addition to the Strategic National Stockpile," said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. "Anthim is demonstrating the potential to deliver significant therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

Dr. Posillico will be presenting an update on Anthim's development program at the 10th Annual BIO Investor Forum in San Francisco on October 26.

"We have successfully manufactured Anthim at commercial scale, and look forward to finalizing our commercial production process to ensure the large-scale capacity needed to deliver high quality, consistent quantities of Anthim for the long term," added James Porter, Vice President of Development and Manufacturing at Elusys.

Anthrax is a life-threatening infectious disease caused by the bacterium Bacillus anthracis and remains one
'/>"/>

SOURCE Elusys Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection
2. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
3. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
4. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
7. CareFusion Initiates Class I Recall of EnVe Ventilators
8. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
9. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
10. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... TWi Pharmaceuticals, Inc. ("TWi") today announced ... with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals ... Inc. (individually and collectively, "Takeda") to settle and ... generic dexlansoprazole delayed release capsules for oral administration ... Abbreviated New Drug Application for TWi,s generic product ...
(Date:4/25/2015)... -- Hospira, Inc. (NYSE: HSP ... sprach heute auf der jährlichen Konferenz der Europäischen ... London über die Bedeutung von ... für Patienten. Das Unternehmen kündigte auch ... Titel „Why extrapolation is paramount to achieving ...
(Date:4/24/2015)... 24, 2015 Today, humanity takes a massive step ... and fat-free cronuts: 1-800 CONTACTS announces their new Apple Watch ... two taps. Two taps. New contacts. From your ... The app also features LensGauge which helps keep track of ... need to reorder. "Since our inception, we,ve been ...
Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2
(Date:4/27/2015)... Mirada, CA (PRWEB) April 27, 2015 ... minimally invasive treatments for nail fungi and infections. Onychomycosis, ... to affect up to 10% of adults in the ... fragility, and irregularity in thickness. , Healthpointe’s ... Institute , a branch dedicated to providing quality skincare ...
(Date:4/27/2015)... Miami, FL (PRWEB) April 27, 2015 ... policies from arresting nonviolent drug offenders to providing drug ... by Nepr on April 8th. Several states, ... cut state costs revolving incarceration. Texas has formed community ... populace. According to The Council of State Governments ...
(Date:4/27/2015)... April 27, 2015 Consumer Choice ... Service Providers in their respective sectors for Ottawa. We ... year’s winners; your dedication to superior service has resonated ... Canada, Consumer Choice Award gathers opinions, perceptions and expectations ... All winners have gone through a rigorous selection process ...
(Date:4/27/2015)... 2015 The Sanford J. Grossman Charitable ... Grossman, PhD, has committed $3 million to establish the ... Inflammatory Bowel Disease at the Icahn School of Medicine ... personalized medicine for treatment of Crohn’s disease, with the ... Crohn’s Disease, a chronic inflammatory disorder of the bowel ...
(Date:4/27/2015)... April 27, 2015 Final Cut Pro ... footage with ProTelestrator from Pixel Film Studios. A telestrator is ... sketch over a moving or still video image. Telestrators are ... analyze sports plays or incoming weather patterns. , After users ... then adjust the frame slider to control the speed of ...
Breaking Medicine News(10 mins):Health News:Southern California Healthpointe Clinics Now Treating Nail Fungus 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 3Health News:2015 Ottawa Consumer Choice Award-Winners 2Health News:2015 Ottawa Consumer Choice Award-Winners 3Health News:2015 Ottawa Consumer Choice Award-Winners 4Health News:2015 Ottawa Consumer Choice Award-Winners 5Health News:2015 Ottawa Consumer Choice Award-Winners 6Health News:2015 Ottawa Consumer Choice Award-Winners 7Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 2Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2
... has been discovered by researchers at Seoul National University. It ... highly expressed in lung cancer cells and also that patients ... study is published on March 31 in the open-access journal ... of the world,s most common cancers and a leading cause ...
... cancer organizations shows rates of death in the United States from ... and 2007. The findings come from the latest Annual Report to ... also finds that the overall rate of new cancer diagnoses for ... 1 percent per year for the same period. Edward J. ...
... from the University of Pittsburgh and Stanford University discovered ... role in the ability of one the world,s most ... possible role of similarly errant proteins in other diseases. ... the National Academy of Sciences ( PNAS ) ...
... the obesity epidemic, the National Institutes of Health is ... for NIH Obesity Research. More than one-third ... percent of the nation,s children are now obese, which ... including type 2 diabetes, heart disease, high blood pressure, ...
... a total of $383,000 for chronic obstructive pulmonary disease ... Institute (NHLBI), part of the National Institutes of Health, ... COPD Learn More Breathe Better campaign and will be ... The contract supports community-based public health efforts to ...
... continues to grow. Following the successful First International ... Second International Conference on Immune Tolerance will bring ... and insights into the mechanisms and treatment of ... inflammation and cancer. This Conference is supported by ...
Cached Medicine News:Health News:Pitt-Stanford research suggests aimless proteins crucial to disease 2Health News:New strategic plan for NIH obesity research seeks to curb epidemic 2Health News:NHLBI funds 9 organizations to improve awareness of COPD 2Health News:2nd International Conference on Immune Tolerance 2
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
... Electro-Dermatome. This is the only powered 6-inch ... graft can cover most adult hands or ... dermatome has been designed to run more ... considerably and the handle temperature is much ...
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec™ button tip manipulator, 0.50 mm diameter button tip angled 45, 15.0 mm from end (3/bx, 1 bx/ca). May be used for IOL manipulation or iris retraction. Sterile....
Medicine Products: